Determining the specificity of HLA antibodies is arguably one of the most important contributions by the HLA laboratory today. For patients that have low-to-moderate levels of antibody, using a ...
Somatic mutations in HLA genes were detected in the tumor data of five patients, and somatic HLA gene loss of heterozygosity was identified in the tumor data of five patients. Complete or partial ...
Greenwich LifeSciences reports preliminary HLA data from Phase III trial FLAMINGO-01 evaluating GLSI-100 for preventing breast cancer recurrences. Greenwich LifeSciences, Inc. provided an update on ...
A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma. This is an ASCO Meeting Abstract from the 2023 ASCO Annual ...
GLSI-100 treatment in HER2-positive breast cancer patients shows increased immune responses, with visible skin reactions indicating efficacy. Both HLA-A*02 and non-HLA-A*02 patients exhibited immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results